<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-id journal-id-type="hwp">sptar</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28614995</article-id><article-id pub-id-type="pmc">5933634</article-id><article-id pub-id-type="doi">10.1177/1753465817710596</article-id><article-id pub-id-type="publisher-id">10.1177_1753465817710596</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Ease of use of tobramycin inhalation powder compared with nebulized
tobramycin and colistimethate sodium: a crossover study in cystic fibrosis
patients with pulmonary <italic>Pseudomonas aeruginosa</italic>
infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Greenwood</surname><given-names>James</given-names></name><aff id="aff1-1753465817710596">Liverpool Heart and Chest Hospital NHS
Foundation Trust, Thomas Drive, Liverpool, UK</aff></contrib><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Carsten</given-names></name><aff id="aff2-1753465817710596">Department of Pediatric Pneumology and
Immunology, Cystic Fibrosis Centre Berlin, Charit&#x000e9;&#x02013;University Medicine
Berlin, Berlin, Germany</aff></contrib><contrib contrib-type="author"><name><surname>Sommerwerck</surname><given-names>Urte</given-names></name><aff id="aff3-1753465817710596">Department of Pneumology, Ruhrlandklinik, West
German Lung Center, University Hospital of Essen, University Duisburg-Essen,
Essen, Germany</aff></contrib><contrib contrib-type="author"><name><surname>Nash</surname><given-names>Edward F</given-names></name><aff id="aff4-1753465817710596">West Midlands Adult Cystic Fibrosis Centre,
Heart of England NHS Foundation Trust, Birmingham, UK</aff></contrib><contrib contrib-type="author"><name><surname>Tamm</surname><given-names>Michael</given-names></name><aff id="aff5-1753465817710596">Clinic of Pneumology and Respiratory Cell
Research, University Hospital, Basel, Switzerland</aff></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Weihua</given-names></name><aff id="aff6-1753465817710596">Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA</aff></contrib><contrib contrib-type="author"><name><surname>Mastoridis</surname><given-names>Paul</given-names></name><aff id="aff7-1753465817710596">Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA</aff></contrib><contrib contrib-type="author"><name><surname>Debonnett</surname><given-names>Laurie</given-names></name><aff id="aff8-1753465817710596">Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA</aff></contrib><contrib contrib-type="author"><name><surname>Hamed</surname><given-names>Kamal</given-names></name><xref ref-type="corresp" rid="corresp1-1753465817710596"/><aff id="aff9-1753465817710596">Novartis Pharmaceuticals Corporation, East
Hanover, NJ 07936-1080, USA</aff></contrib></contrib-group><author-notes><corresp id="corresp1-1753465817710596"><email>kamal.hamed@novartis.com</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><volume>11</volume><issue>7</issue><fpage>249</fpage><lpage>260</lpage><history><date date-type="received"><day>21</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>3</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-1753465817710596"><title>Background:</title><p>This study assessed the ease of use of tobramycin inhalation powder (TIP)
administered <italic>via</italic> T-326 inhaler <italic>versus</italic>
tobramycin inhalation solution (TIS) and colistimethate sodium (COLI), both
administered <italic>via</italic> nebulizers, for the treatment of chronic
pulmonary <italic>Pseudomonas aeruginosa</italic> infection in patients with
cystic fibrosis (CF).</p></sec><sec id="section2-1753465817710596"><title>Methods:</title><p>A real-world, open-label, crossover, interventional phase IV study was
conducted in CF patients aged &#x02a7e;6 years with forced expiratory volume in 1
second (FEV<sub>1</sub>) &#x02a7e;25% to &#x02a7d;90% predicted. Patients were assigned to
one of the three treatment arms in Cycle 1; all patients received TIP in
Cycle 2. Each cycle consisted of 28 days on and 28 days off the
treatment.</p></sec><sec id="section3-1753465817710596"><title>Results:</title><p>A total of 60 patients [mean (standard deviation) age, 27.6 (8.4) years] were
allocated to three treatment arms [TIS/TIP (<italic>n</italic> = 14);
COLI/TIP (<italic>n</italic> = 28); TIP/TIP (<italic>n</italic> = 18)] in
Cycle 1. The mean total administration time, which included device setup and
cleaning, in Cycle 1 <italic>versus</italic> Cycle 2 for TIS/TIP, COLI/TIP,
and TIP/TIP arms were 37.0 <italic>versus</italic> 5.0 min, 16.4
<italic>versus</italic> 3.8 min, and 4.2 <italic>versus</italic> 3.4
min, respectively. The difference in mean total administration time was
significantly shorter in Cycle 2 than in Cycle 1 for TIS/TIP
(<italic>p</italic> = 0.0112) and COLI/TIP (<italic>p</italic> = 0.0016)
arms. Overall, 12 patients were found to have contaminated devices across
the two treatment cycles. In the TIP/TIP arm, no contamination of the T-326
inhaler was observed in either cycle. Treatment satisfaction, assessed by
the Treatment Satisfaction Questionnaire for Medication and ACCEPT&#x000ae;
questionnaire, was better overall for TIP compared with TIS and COLI. There
were no unexpected adverse events and most were mild or moderate in
intensity.</p></sec><sec id="section4-1753465817710596"><title>Conclusion:</title><p>The T-326 inhaler used to deliver TIP was easy to use, required shorter total
administration time, and was much less frequently contaminated than the
nebulizers. The safety findings observed for TIP were generally consistent
with its established safety profile.</p></sec></abstract><kwd-group><kwd>device contamination</kwd><kwd>ease of use</kwd><kwd>nebulizer</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd><kwd>T-326 inhaler</kwd><kwd>tobramycin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="section5-1753465817710596"><title>Introduction</title><p>Cystic fibrosis (CF) patients are generally susceptible to respiratory infection
caused by <italic>Pseudomonas aeruginosa</italic> (<italic>Pa</italic>), which is
associated with progressive lung function decline and increased morbidity and mortality.<sup><xref rid="bibr1-1753465817710596" ref-type="bibr">1</xref></sup>,<sup><xref rid="bibr2-1753465817710596" ref-type="bibr">2</xref></sup> Tobramycin inhalation solution (TIS) has been established as an effective
inhaled antibiotic for the treatment of chronic <italic>Pa</italic> pulmonary
infection in patients with CF aged &#x02a7e;6 years.<sup><xref rid="bibr3-1753465817710596" ref-type="bibr">3</xref></sup>,<sup><xref rid="bibr4-1753465817710596" ref-type="bibr">4</xref></sup> Colistimethate sodium (COLI) is also indicated for treating chronic pulmonary
infection due to <italic>Pa</italic> in adult and pediatric CF patients.<sup><xref rid="bibr5-1753465817710596" ref-type="bibr">5</xref></sup> The administration of nebulized TIS and COLI for the treatment of
<italic>Pa</italic> infection is complex, time consuming, and places a high
burden on CF patients and their caregivers, posing a significant challenge to
treatment adherence.<sup><xref rid="bibr4-1753465817710596" ref-type="bibr">4</xref></sup>,<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup>,<sup><xref rid="bibr7-1753465817710596" ref-type="bibr">7</xref></sup> In addition, nebulizers require regular maintenance, consisting of cleaning,
disinfection, and drying for each use to minimize microbial contamination.<sup><xref rid="bibr8-1753465817710596" ref-type="bibr">8</xref></sup>,<sup><xref rid="bibr9-1753465817710596" ref-type="bibr">9</xref></sup> Moreover, pathogens are commonly isolated from nebulizers and there is a
concern that the nebulizer equipment may contribute to bacterial infection in the
lower airways of CF patients.<sup><xref rid="bibr2-1753465817710596" ref-type="bibr">2</xref></sup>,<sup><xref rid="bibr9-1753465817710596" ref-type="bibr">9</xref></sup> Tobramycin inhalation powder (TIP) has been developed for the suppressive
management of pulmonary infection due to <italic>Pa</italic> in CF patients aged &#x02a7e;6 years.<sup><xref rid="bibr10-1753465817710596" ref-type="bibr">10</xref></sup> TIP, delivered <italic>via</italic> the T-326 inhaler, was reported to have a
safety and efficacy profile similar to that of TIS but with a substantially
simplified method of administration, which has translated into increased patient
convenience and adherence.<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup>,<sup><xref rid="bibr11-1753465817710596" ref-type="bibr">11</xref></sup><sup><xref rid="bibr12-1753465817710596" ref-type="bibr"/>&#x02013;</sup><sup><xref rid="bibr13-1753465817710596" ref-type="bibr">13</xref></sup> This study was designed to compare the ease of use of TIP administered
<italic>via</italic> the T-326 inhaler (Novartis Pharma AG, Basel, Switzerland)
with TIS and COLI, both administered <italic>via</italic> nebulizers. Furthermore,
the prevalence of microbial contamination of the devices used was also compared in
this study.</p></sec><sec sec-type="methods" id="section6-1753465817710596"><title>Methods</title><p>This open-label, crossover, interventional, phase IV, 20-week trial was conducted at
22 centers in the United Kingdom (8), Spain (5), Germany (4), Switzerland (3), and
Ireland (2). The study protocol was reviewed by an independent ethics
committee/institutional review board for each center and was conducted according to
the ethical principles of the Declaration of Helsinki. Written informed consent was
obtained from each patient or their representative (parent or legal guardian). CF
patients aged &#x02a7e;6 years with forced expiratory volume in 1 second (FEV<sub>1</sub>)
&#x02a7e;25% to &#x02a7d;90% predicted were recruited if they had documented use of either COLI,
TIS, or TIP for at least one cycle, and two positive cultures for
<italic>Pa</italic> (either sputum, deep cough throat swab, or bronchoalveolar
lavage), within the last 6 months. Patients with a current or past history of
<italic>Burkholderia cepacia</italic> complex infection within 2 years prior to
screening, hemoptysis &#x0003e;60 ml within 30 days of Visit 2, serum creatinine level &#x02a7e;2
mg/dl, or a history of hearing loss or chronic tinnitus deemed clinically
significant by the investigator, were excluded from the study.</p><sec id="section7-1753465817710596"><title>Study design</title><p>The study consisted of 6 visits (<xref ref-type="fig" rid="fig1-1753465817710596">Figure 1(a)</xref>) over 20 weeks. Patients were assigned to one of the
three treatment arms: COLI/TIP, TIS/TIP, or TIP/TIP.</p><fig id="fig1-1753465817710596" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(a) Study design, (b) Patient disposition.</p><p><sup>*</sup>Patients on continuous COLI were to observe a 24-h COLI-free
period before the start of TIP at Visit 4.</p><p>Note: Patients with COLI could follow a cyclic or noncyclic regimen
dependent on local treatment practice.</p><p>AEs, adverse events; COLI, colistimethate sodium; TIP, tobramycin
inhalation powder; TIS, tobramycin inhalation solution.</p></caption><graphic xlink:href="10.1177_1753465817710596-fig1"/></fig><p>In Cycle 1, patients in the COLI/TIP arm received nebulized COLI, 1 or 2 million
units two or three times per day depending on local treatment guidelines for 56
days (no off-treatment period), administered using the patient&#x02019;s usual
nebulizer, and patients in the TIS/TIP arm received nebulized TIS, 300 mg twice
daily for 28 days administered using the patient&#x02019;s usual nebulizer, followed by
28 days off treatment. In Cycle 2 of these two arms, and in both Cycles 1 and 2
of the TIP/TIP arm, patients were treated with TIP, 112 mg (4 &#x000d7; 28 mg capsules)
twice daily for 28 days followed by 28 days off treatment.</p><p>The three inhaled antibiotics were compared with each other with respect to ease
of use in Cycle 1 in a real-world setting. Cycle 2 allowed the direct assessment
of the &#x02018;switch experience&#x02019; from nebulized antibiotics to TIP. The study was
open-label as blinding the delivery device for TIP was not feasible, because a
double-dummy design would have imposed a great burden on the patients for the
feasibility of the study and conflict with measurement of the primary endpoint
(ease of use).</p></sec><sec id="section8-1753465817710596"><title>Efficacy and patient-reported outcomes</title><p>Ease of use was measured by the mean cumulative time required to administer study
treatments, including device setup/preparation, drug administration, and device
cleaning (including disinfection, where applicable). The readiness of use of the
study treatment was assessed as the sum of the time of start to the time of
completion of delivery device preparation and the time of start to the time of
completion of study treatment preparation. In addition, patient&#x02019;s satisfaction
and acceptance of the treatment were assessed<sup><xref rid="bibr14-1753465817710596" ref-type="bibr">14</xref></sup> by using the Treatment Satisfaction Questionnaire for Medication (TSQM)
and Chronic Treatment ACCEPTance (ACCEPT&#x000ae;) questionnaire.<sup><xref rid="bibr15-1753465817710596" ref-type="bibr">15</xref></sup>,<sup><xref rid="bibr16-1753465817710596" ref-type="bibr">16</xref></sup> Patients aged &#x02a7e;13 years completed the questionnaires by themselves in
their local language in a quiet setting, and patients aged &#x0003c;13 years
completed the questionnaires with the assistance of their parents or guardians.
A patient preference survey was also conducted to evaluate the patients&#x02019;
experience in switching from COLI or TIS to TIP.</p><p>Microbial contamination of the delivery device with <italic>Pa</italic> and other
pathogens was analyzed in terms of light, moderate or heavy growth. The minimum
inhibitory concentration (MIC) of tobramycin and other selected antibiotics for
<italic>Pa</italic> isolated from patients&#x02019; specimens was assessed. The
other efficacy measures evaluated were change in sputum <italic>Pa</italic>
density (log<sub>10</sub> colony-forming units (CFU)/g sputum), changes in
clinical laboratory results and lung function [FEV<sub>1</sub>, forced vital
capacity (FVC), and forced expiratory flow between 25&#x02013;75% of FVC
(FEF<sub>25&#x02013;75%</sub>)].</p><p>The delivery devices used by CF patients were assessed for microbial
contamination and swabs were collected from four locations on the nebulizer
(mouthpiece, reservoir cup, filter, and tubing) and from the mouthpiece of the
T-326 inhaler. Microbial contamination of the nebulizers was assessed at Visits
2 and 3 (the start and end of the first treatment period), Visits 4 and 5 (start
and end of the second treatment period) and Visit 6 (end of study or
discontinuation visit). Patients on TIP brought to their study visits the T-326
device used in the last week of TIP treatment. No assessment was required for
the device at Visits 2 and 4, when the patients started the TIP treatment
periods. If patients used nebulizers for inhaling any other medications they
brought these nebulizers to their study Visits 2 and 6 for testing. Sputum
specimens were collected from patients at clinic visits [1 (screening), 2, 3, 4,
5, and 6] for quantitative (CFUs) or semiquantitative culture of
<italic>Pa</italic> (light, moderate, or heavy growth) and semiquantitative
culture for non-<italic>Pa</italic> pathogens. These assessments were performed
by a central laboratory. Cultures were performed on a variety of media designed
to maximize growth of the pathogens most commonly isolated from the sputum of
patients with CF. Cultures were evaluated after 24, 48, and 72 h.</p></sec><sec id="section9-1753465817710596"><title>Safety assessments</title><p>Safety evaluations consisted of the incidence and intensity of all adverse events
(AEs), including cough, and serious AEs (SAEs) during both on- and off-treatment
periods; physical condition; hematology and blood chemistry; urinalysis;
audiology; and body weight.</p></sec><sec id="section10-1753465817710596"><title>Sample size and statistical analysis</title><p>A sample size of 15 patients per arm had 91% power to detect a difference in mean
total administration time of 14 min as observed between TIS and TIP in the EAGER study,<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup> assuming a standard deviation (SD) of difference of 15 min or less and
using a paired Student&#x02019;s <italic>t</italic>-test with a 0.05 two-sided
significance level. These calculations were performed <italic>a
priori</italic>.</p><p>All data summaries and analyses were performed primarily within the study arms as
the characteristics of the patients may vary among these arms. Summary
statistics were provided for the mean total administration time per cycle by
treatment arm and for within-patient differences in mean total administration
time between treatments (Cycle 2&#x02212;Cycle 1) by treatment arm. Safety analyses were
based on descriptive statistics for AEs, cough rates, inhalation-associated
cough, SAEs, airway reactivity, laboratory test results, audiology (where
assessed), and vital signs that were summarized for each treatment and treatment
cycle by arm.</p></sec></sec><sec sec-type="results" id="section11-1753465817710596"><title>Results</title><sec id="section12-1753465817710596"><title>Study population</title><p>Of the 60 patients enrolled, the majority (51 patients; 85%) completed the study
and nine patients (15%) discontinued the study. The reasons for discontinuation
are listed in <xref ref-type="fig" rid="fig1-1753465817710596">Figure
1(b)</xref>. Patient baseline demographic and characteristics were
comparable across the treatment arms. The mean age (SD) of the patient
population was 27.6 years (&#x000b1;8.40; <xref ref-type="table" rid="table1-1753465817710596">Table 1</xref>). A total of four pediatric
patients were enrolled, two patients each in the age groups of 6&#x02013;12 and 13&#x02013;17
years.</p><table-wrap id="table1-1753465817710596" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline demographic and disease characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_1753465817710596-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Baseline characteristics<sup><xref ref-type="table-fn" rid="table-fn1-1753465817710596">*</xref></sup></th><th align="left" rowspan="1" colspan="1">TIS/TIP<break/><italic><italic>N</italic>
=</italic> 14</th><th align="left" rowspan="1" colspan="1">COLI/TIP<break/><italic>N</italic> = 28</th><th align="left" rowspan="1" colspan="1">TIP/TIP<break/><italic><italic>N</italic>
=</italic> 18</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), mean (SD)</td><td rowspan="1" colspan="1">27.4 (6.82)</td><td rowspan="1" colspan="1">28.4 (9.86)</td><td rowspan="1" colspan="1">26.6 (7.25)</td></tr><tr><td rowspan="1" colspan="1">Age group (&#x02a7e;18 years), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">13 (92.9)</td><td rowspan="1" colspan="1">27 (96.4)</td><td rowspan="1" colspan="1">16 (88.9)</td></tr><tr><td rowspan="1" colspan="1">Sex (male), <italic>n</italic> (%)</td><td rowspan="1" colspan="1">10 (71.4)</td><td rowspan="1" colspan="1">18 (64.3)</td><td rowspan="1" colspan="1">11 (61.1)</td></tr><tr><td rowspan="1" colspan="1">Race, White, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">14 (100.0)</td><td rowspan="1" colspan="1">28 (100.0)</td><td rowspan="1" colspan="1">18 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>), mean (SD)</td><td rowspan="1" colspan="1">21.7 (3.19)</td><td rowspan="1" colspan="1">21.4 (3.12)</td><td rowspan="1" colspan="1">21.2 (3.83)</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>% predicted, mean (SD)<sup><xref ref-type="table-fn" rid="table-fn2-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1">55.0 (17.02)</td><td rowspan="1" colspan="1">59.1 (19.42)</td><td rowspan="1" colspan="1">62.6 (17.78)</td></tr><tr><td rowspan="1" colspan="1">FVC% predicted, mean (SD)<sup><xref ref-type="table-fn" rid="table-fn2-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1">67.7 (18.34)</td><td rowspan="1" colspan="1">80.1 (19.44)</td><td rowspan="1" colspan="1">78.6 (15.45)</td></tr><tr><td rowspan="1" colspan="1">FEF<sub>25&#x02013;75%</sub> predicted, mean (SD)<sup><xref ref-type="table-fn" rid="table-fn2-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1">30.6 (21.19)</td><td rowspan="1" colspan="1">32.5 (22.27)</td><td rowspan="1" colspan="1">37.3 (26.79)</td></tr><tr><td rowspan="1" colspan="1">Sputum density of <italic>Pa</italic> (log<sub>10</sub>
CFU/ml) &#x02013; sum of all biotypes, mean (SD)<sup><xref ref-type="table-fn" rid="table-fn3-1753465817710596">&#x02021;</xref></sup></td><td rowspan="1" colspan="1">7.8 (1.88)</td><td rowspan="1" colspan="1">6.9 (2.22)</td><td rowspan="1" colspan="1">6.8 (2.46)</td></tr><tr><td colspan="2" rowspan="1"><italic>Pa</italic> tobramycin MIC,
<italic>n</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003e;8 &#x000b5;g/ml</td><td rowspan="1" colspan="1">6 (42.9)</td><td rowspan="1" colspan="1">6 (21.4)</td><td rowspan="1" colspan="1">6 (33.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02a7d;8 &#x000b5;g/ml</td><td rowspan="1" colspan="1">8 (57.1)</td><td rowspan="1" colspan="1">21 (75.0)</td><td rowspan="1" colspan="1">12 (66.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Missing</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (3.6)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Current use of long-acting bronchodilator,
<italic>n</italic> (%)</td><td rowspan="1" colspan="1">1 (7.1)</td><td rowspan="1" colspan="1">5 (17.9)</td><td rowspan="1" colspan="1">10 (55.6)</td></tr><tr><td rowspan="1" colspan="1">Current use of short-acting bronchodilator,
<italic>n</italic> (%)</td><td rowspan="1" colspan="1">3 (21.4)</td><td rowspan="1" colspan="1">7 (25.0)</td><td rowspan="1" colspan="1">11 (61.1)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1753465817710596"><label>*</label><p>Baseline is defined as the last value before the first dose of study
drug.</p></fn><fn id="table-fn2-1753465817710596"><label>&#x02020;</label><p>Recalculated to avoid calculation errors and use of different
formulas to calculate % predicted values by local labs,
FEV<sub>1</sub>% predicted/FVC% predicted/FEF<sub>25&#x02013;75%</sub>
predicted are derived according to Quanjer et al.<sup><xref rid="bibr27-1753465817710596" ref-type="bibr">27</xref></sup></p></fn><fn id="table-fn3-1753465817710596"><label>&#x02021;</label><p>Overall density defined as the sum of biotypes (mucoid, dry and small
colony variants).</p></fn><fn id="table-fn4-1753465817710596"><p>CFU, colony-forming unit; COLI, colistimethate sodium; FEF, forced
expiratory flow; FEV<sub>1</sub>, forced expiratory volume in 1
second; FVC, forced vital capacity; MIC, minimum inhibitory
concentration; <italic>Pa, Pseudomonas aeruginosa</italic>; SD,
standard deviation; TIP, tobramycin inhalation powder; TIS,
tobramycin inhalation solution.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section13-1753465817710596"><title>Efficacy results</title><sec id="section14-1753465817710596"><title>Ease of use</title><p>Ease of use was considered a composite indicator of the speed, simplicity,
and convenience of the study treatments. The mean total administration time
including the time required to set up the delivery device, administer the
drug, and clean the delivery device was significantly shorter in Cycle 2
(TIP treatment) than in Cycle 1 for the TIS/TIP and COLI/TIP arms (<xref ref-type="table" rid="table2-1753465817710596">Table 2</xref>). However,
the cumulative administration time between the treatment cycles remained
similar for the TIP/TIP arm (<xref ref-type="table" rid="table2-1753465817710596">Table 2</xref>). The mean administration
time (excluding the setup, cleaning, and disinfection times) was
significantly shorter in Cycle 2 than in Cycle 1 for all three treatment
arms [difference in mean administration time, Cycle 2&#x02212;Cycle 1: TIS/TIP, &#x02212;9.8
(<italic>p</italic> = 0.0005); COLI/TIP, &#x02212;5.3 (<italic>p</italic> =
0.0001); TIP/TIP, &#x02212;0.3 (<italic>p</italic> = 0.0464)].</p><table-wrap id="table2-1753465817710596" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Analysis of mean total administration<sup><xref ref-type="table-fn" rid="table-fn7-1753465817710596">*</xref></sup> time in minutes.</p></caption><alternatives><graphic xlink:href="10.1177_1753465817710596-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">TIS/TIP<break/><italic>N</italic> = 14</th><th align="left" rowspan="1" colspan="1">COLI/TIP<break/><italic><italic>N</italic>
=</italic> 28</th><th align="left" rowspan="1" colspan="1">TIP/TIP<break/><italic><italic>N</italic>
=</italic> 18</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cycle 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>N</italic></td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">37.0 (22.06)</td><td rowspan="1" colspan="1">16.4 (9.54)</td><td rowspan="1" colspan="1">4.2 (2.02)</td></tr><tr><td rowspan="1" colspan="1">Cycle 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>N</italic></td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">5.0 (2.04)</td><td rowspan="1" colspan="1">3.8 (1.70)</td><td rowspan="1" colspan="1">3.4 (2.06)</td></tr><tr><td colspan="2" rowspan="1">Time difference between Cycles 1 and 2<sup><xref ref-type="table-fn" rid="table-fn8-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>N</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">Mean (SD)</td><td rowspan="1" colspan="1">&#x02212;32.7 (23.90)</td><td rowspan="1" colspan="1">&#x02212;13.3 (10.35)</td><td rowspan="1" colspan="1">&#x02212;0.2 (0.92)</td></tr><tr><td rowspan="1" colspan="1">Cycle comparison</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;95% CI</td><td rowspan="1" colspan="1">(&#x02212;54.8, &#x02212;10.6)</td><td rowspan="1" colspan="1">(&#x02212;20.3, &#x02212;6.4)</td><td rowspan="1" colspan="1">(&#x02212;0.8, 0.4)</td></tr><tr><td rowspan="1" colspan="1"><italic>&#x02003;p</italic>-value<sup><xref ref-type="table-fn" rid="table-fn9-1753465817710596">&#x02021;</xref></sup></td><td rowspan="1" colspan="1">0.0112</td><td rowspan="1" colspan="1">0.0016</td><td rowspan="1" colspan="1">0.4380</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn5-1753465817710596"><p>Note: If the disinfection time was reported at least once in a
day, all total administration times of that day were considered
for calculating patient&#x02019;s mean total administration time. This
applies for patients on TIS or COLI treatment in Cycle 1.</p></fn><fn id="table-fn6-1753465817710596"><p>Data of only patients with available mean total administration
time of initial and second cycle were considered.</p></fn><fn id="table-fn7-1753465817710596"><label>*</label><p>Total administration time, device setup time + administration
time + device cleaning time + disinfection time (if
available).</p></fn><fn id="table-fn8-1753465817710596"><label>&#x02020;</label><p>Time difference in the mean total administration time was
calculated using within-patient differences, Cycle 2&#x02212;Cycle
1.</p></fn><fn id="table-fn9-1753465817710596"><label>&#x02021;</label><p><italic>p</italic>-values calculated using the paired Student&#x02019;s
<italic>t</italic>-test and 95% CIs for the mean difference
were displayed.</p></fn><fn id="table-fn10-1753465817710596"><p>CI, confidence interval; COLI, colistimethate sodium; SD,
standard deviation; TIP, tobramycin inhalation powder; TIS,
tobramycin inhalation solution.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section15-1753465817710596"><title>Microbial contamination of devices</title><p>A total of 12 patients were found to have contaminated devices across the
treatment cycles; 11 patients had contaminated nebulizers and one patient
had a contaminated T-326 inhaler (<xref ref-type="table" rid="table3-1753465817710596">Table 3</xref>): COLI/TIP arm, 9 (32.1%);
TIS/TIP arm, 2 (14.3%); and TIP/TIP arm, 1 (5.6%). In the COLI/TIP arm, the
majority of pathogens were isolated (only once) from the devices that
delivered COLI at Visits 2 and 3. Except for one patient with
<italic>Staphylococcus aureus</italic> infection in the COLI/TIP arm, no
patient had the same pathogen isolated from the delivery device and sputum
at Visits 2 and 3. In the TIP/TIP arm, no contamination was observed in the
T-326 inhaler during either Cycle 1 or 2.</p><table-wrap id="table3-1753465817710596" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Delivery device cultures (density categories for pathogens including
<italic>Pa</italic>).</p></caption><alternatives><graphic xlink:href="10.1177_1753465817710596-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Cycle/visit</th><th align="left" rowspan="1" colspan="1">Device</th><th align="left" rowspan="1" colspan="1">Pathogen</th><th align="left" rowspan="1" colspan="1">
<italic>N</italic>
<sup><xref ref-type="table-fn" rid="table-fn13-1753465817710596">*</xref></sup>
</th><th align="left" rowspan="1" colspan="1">Light</th><th align="left" rowspan="1" colspan="1">Moderate</th><th align="left" rowspan="1" colspan="1">Heavy</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">TIS/TIP (<italic>N</italic> = 14)</td></tr><tr><td rowspan="1" colspan="1">Cycle 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 2 (BSL)</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 3</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Cycle 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 4</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"><italic>Pseudomonas aeruginosa</italic> biotype 2,
dry</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 (100.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 5</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">T-326 inhaler<sup><xref ref-type="table-fn" rid="table-fn14-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1">
<italic>Staphylococcus aureus</italic>
</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 (100.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="7" rowspan="1">COLI/TIP (<italic>N</italic> = 28)</td></tr><tr><td rowspan="1" colspan="1">Cycle 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 2 (BSL)</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1">
<italic>Acinetobacter baumannii</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (14.3)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Acinetobacter junii</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Acinetobacter lwoffi</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">2 (28.6)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Haemophilus parainfluenza</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Ochrobactrum anthropi</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (14.3)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Pseudomonas fluorescens</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Pseudomonas putida</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Pseudomonas stutzeri</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Serratia liquefaciens</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Sphingobacterium multivorum</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Stenotrophomonas maltophilia</italic>
</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">1 (14.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 3</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"><italic>Acinetobacter species</italic> unspecified</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Chryseobacterium indologenes</italic>
</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Delftia acidovorans</italic>
</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Pseudomonas fluorescens</italic>
</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">2 (33.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Sphingomonas paucimobilis</italic>
</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (16.7)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<italic>Staphylococcus aureus</italic>
</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">1 (16.7)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Cycle 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 4</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 5</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">T-326 inhaler</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="7" rowspan="1">TIP/TIP (<italic>N</italic> = 18)</td></tr><tr><td rowspan="1" colspan="1">Cycle 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 2 (BSL)</td><td rowspan="1" colspan="1">Nebulizer<sup><xref ref-type="table-fn" rid="table-fn15-1753465817710596">&#x02021;</xref></sup></td><td rowspan="1" colspan="1"><italic>Pseudomonas aeruginosa</italic> biotype 2,
dry</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">1 (100.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 3</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">T-326 inhaler</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Cycle 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Visit 4</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Visit 5</td><td rowspan="1" colspan="1">Nebulizer</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">T-326 inhaler</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn11-1753465817710596"><p>Note: Commercial packs of TIP were used at Visit 4 (start of
Cycle 2) by each patient.</p></fn><fn id="table-fn12-1753465817710596"><p>All nebulizers used by the patients were analyzed, including
those on other inhaled medications (e.g. mucolytics).</p></fn><fn id="table-fn13-1753465817710596"><label>*</label><p>Number of patients with any contaminated delivery device.</p></fn><fn id="table-fn14-1753465817710596"><label>&#x02020;</label><p><italic>S. aureus</italic> isolated (light growth) from one T-326
inhaler was not present in the patient&#x02019;s sputum.</p></fn><fn id="table-fn15-1753465817710596"><label>&#x02021;</label><p><italic>Pa</italic> (moderate growth) was isolated from the
nebulizer (medication not specified) at Visit 2.</p></fn><fn id="table-fn16-1753465817710596"><p>BSL, baseline; COLI, colistimethate sodium; TIP, tobramycin
inhalation powder; TIS, tobramycin inhalation solution.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section16-1753465817710596"><title>Pseudomonas aeruginosa sputum density and MIC</title><p>The absolute change in the number of <italic>Pa</italic> CFUs in the sputum
was assessed after a period of up to 28 days of treatment. At Visit 3 (Cycle
1), the mean log reduction in <italic>Pa</italic> for the sum of all
biotypes was 1.4 log<sub>10</sub> CFU in the TIS/TIP arm, 0.6
log<sub>10</sub> CFU in the COLI/TIP arm, and 1.7 log<sub>10</sub> CFU
in the TIP/TIP arm. At Visit 5 (Cycle 2), the mean log reduction was
slightly lower for the TIS/TIP arm and was similar for the other two arms.
In general, the result of each biotype was comparable with the result
observed for the sum of all biotypes.</p><p>Tobramycin MIC<sub>50</sub> and MIC<sub>90</sub> values showed that there was
a 1-fold dilution increase in the tobramycin MICs at Visit 5 compared with
Visit 3 for the TIS/TIP arm (MIC<sub>50</sub>: 4 &#x003bc;g/ml
<italic>versus</italic> 2 &#x003bc;g/ml; MIC<sub>90</sub>: 512 &#x003bc;g/ml
<italic>versus</italic> 256 &#x003bc;g/ml) and the COLI/TIP arm
(MIC<sub>50</sub>: 4 &#x003bc;g/ml <italic>versus</italic> 2 &#x003bc;g/ml;
MIC<sub>90</sub>: 32 &#x003bc;g/ml <italic>versus</italic> 16 &#x003bc;g/ml). In the
TIP/TIP arm, the MIC<sub>50</sub> and MIC<sub>90</sub> tobramycin values
were stable up to Visit 5 (2 &#x003bc;g/ml and 64 &#x003bc;g/ml, respectively) and were
further decreased to 1 &#x003bc;g/ml and 32 &#x003bc;g/ml, respectively, at the end of Visit
6.</p></sec><sec id="section17-1753465817710596"><title>Lung function</title><p>The assessment of lung function was an exploratory efficacy endpoint. At
Visit 3, the mean FEV<sub>1</sub>% predicted showed a relative increase from
baseline in the TIS/TIP (2.2%) and COLI/TIP (3.9%) arms and a slight
decrease from baseline in the TIP/TIP arm (&#x02212;2.8%). However, at Visit 5, the
FEV<sub>1</sub>% predicted remained stable across the treatment arms, as
compared with Visit 4. No notable difference was observed
(<italic>p</italic> &#x0003e;0.05) in absolute change from pre-dose value to
the end of on-/off-treatment periods of any visits across all treatment
arms. Similarly, the pre-dose FVC% and FEF<sub>25&#x02013;75%</sub> predicted
relative change from start to end of on- and off-treatment periods at each
visit showed no significant difference in any treatment arm.</p></sec><sec id="section18-1753465817710596"><title>TSQM, ACCEPT&#x000ae; and patient preference questionnaire results</title><p>The median scores for the TSQM questionnaire were high in Cycle 1 and were
either sustained or further improved in Cycle 2 for the majority of domains,
indicating treatment satisfaction in patients receiving TIP (<xref ref-type="table" rid="table4-1753465817710596">Table 4</xref>).
Improvements were reported in Cycle 2 in the COLI/TIP arm for the
effectiveness, convenience, and global satisfaction domains; improvements
were also reported for convenience in the TIS/TIP arm, although the scores
for effectiveness and global satisfaction decreased in Cycle 2 from Cycle 1.
Similar scores were reported between cycles for the TIP/TIP arm with the
exception of a slight decrease in global satisfaction in Cycle 2 for the
TIP/TIP arm.</p><table-wrap id="table4-1753465817710596" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Summary of the TSQM and ACCEPT&#x000ae; questionnaire results.</p></caption><alternatives><graphic xlink:href="10.1177_1753465817710596-table4"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="4" rowspan="1">TIS/TIP<break/><italic>N</italic> = 14<hr/></th><th align="left" colspan="4" rowspan="1">COLI/TIP<break/><italic>N</italic> = 28<hr/></th><th align="left" colspan="4" rowspan="1">TIP/TIP<break/><italic>N</italic> = 18<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">Cycle 1<break/>Visit
3<hr/></th><th align="left" colspan="2" rowspan="1">Cycle 2<break/>Visit
5<hr/></th><th align="left" colspan="2" rowspan="1">Cycle 1<break/>Visit
3<hr/></th><th align="left" colspan="2" rowspan="1">Cycle 2<break/>Visit
5<hr/></th><th align="left" colspan="2" rowspan="1">Cycle 1<break/>Visit
3<hr/></th><th align="left" colspan="2" rowspan="1">Cycle 2<break/>Visit
5<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic><italic>n</italic></italic>
</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic><italic>n</italic></italic>
</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic><italic>n</italic></italic>
</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic><italic>n</italic></italic>
</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic><italic>n</italic></italic>
</th><th align="left" rowspan="1" colspan="1">Median</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">TSQM</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Effectiveness</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">55.6</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">63.9</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">72.2</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">72.2</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">72.2</td></tr><tr><td rowspan="1" colspan="1">Side effects<sup><xref ref-type="table-fn" rid="table-fn18-1753465817710596">*</xref></sup></td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">100.0</td></tr><tr><td rowspan="1" colspan="1">Convenience</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">63.9</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">77.8</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">61.1</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">83.3</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">77.8</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">77.8</td></tr><tr><td rowspan="1" colspan="1">Global satisfaction</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">71.4</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">64.3</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">64.3</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">75.0</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">78.6</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">71.4</td></tr><tr><td rowspan="1" colspan="1">ACCEPT<sup>&#x000ae;<xref ref-type="table-fn" rid="table-fn19-1753465817710596">&#x02020;</xref></sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Medication inconvenience</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">80.0</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">90.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">70.0</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">90.0</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">80.0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">85.0</td></tr><tr><td rowspan="1" colspan="1">Long-term treatment</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">75.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">79.2</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">66.7</td></tr><tr><td rowspan="1" colspan="1">Regime constraints</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">80.0</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">90.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">70.0</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">80.0</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">70.0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">72.5</td></tr><tr><td rowspan="1" colspan="1">Numerous medications, m/M (%)<sup><xref ref-type="table-fn" rid="table-fn20-1753465817710596">&#x02021;</xref></sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes, not easy to accept</td><td rowspan="1" colspan="1">2/11</td><td rowspan="1" colspan="1">18.2</td><td rowspan="1" colspan="1">3/9</td><td rowspan="1" colspan="1">33.3</td><td rowspan="1" colspan="1">0/25</td><td rowspan="1" colspan="1">0.0</td><td rowspan="1" colspan="1">2/23</td><td rowspan="1" colspan="1">8.7</td><td rowspan="1" colspan="1">4/16</td><td rowspan="1" colspan="1">25.0</td><td rowspan="1" colspan="1">3/14</td><td rowspan="1" colspan="1">21.4</td></tr><tr><td rowspan="1" colspan="1">Yes, easy to accept</td><td rowspan="1" colspan="1">4/11</td><td rowspan="1" colspan="1">36.4</td><td rowspan="1" colspan="1">5/9</td><td rowspan="1" colspan="1">55.6</td><td rowspan="1" colspan="1">20/25</td><td rowspan="1" colspan="1">80.0</td><td rowspan="1" colspan="1">16/23</td><td rowspan="1" colspan="1">69.6</td><td rowspan="1" colspan="1">10/16</td><td rowspan="1" colspan="1">62.5</td><td rowspan="1" colspan="1">9/14</td><td rowspan="1" colspan="1">64.3</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">5/11</td><td rowspan="1" colspan="1">45.5</td><td rowspan="1" colspan="1">1/9</td><td rowspan="1" colspan="1">11.1</td><td rowspan="1" colspan="1">5/25</td><td rowspan="1" colspan="1">20.0</td><td rowspan="1" colspan="1">5/23</td><td rowspan="1" colspan="1">21.7</td><td rowspan="1" colspan="1">2/16</td><td rowspan="1" colspan="1">12.5</td><td rowspan="1" colspan="1">2/14</td><td rowspan="1" colspan="1">14.3</td></tr><tr><td rowspan="1" colspan="1">Side effects</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">100.0</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">90.0</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">90.0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">90.0</td></tr><tr><td rowspan="1" colspan="1">Effectiveness</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">83.3</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">58.3</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">75.0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">91.7</td></tr><tr><td rowspan="1" colspan="1">General</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">50.0</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">66.7</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">75.0</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">83.3</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn17-1753465817710596"><p>Each domain score ranges between 0&#x02013;100, with a higher score
indicating a higher treatment satisfaction.</p></fn><fn id="table-fn18-1753465817710596"><label>*</label><p>All values expressed as median values, mean scores in the side
effect domain ranged from 84.2&#x02013;96.8 across treatment arms.</p></fn><fn id="table-fn19-1753465817710596"><label>&#x02020;</label><p>Data are <italic>n</italic>, median unless otherwise
specified.</p></fn><fn id="table-fn20-1753465817710596"><label>&#x02021;</label><p>Percentages are based on M.</p></fn><fn id="table-fn21-1753465817710596"><p>COLI, colistimethate sodium; m, number of patients with the
score; M, number of patients with data of the domain at the
visit; <italic>n</italic>, number of patients with data of the
domain at the visit; TIP, tobramycin inhalation powder; TIS,
tobramycin inhalation solution; TSQM, Treatment Satisfaction
Questionnaire for Medication.</p></fn></table-wrap-foot></table-wrap><p>Regarding the ACCEPT&#x000ae; questionnaire, in Cycle 2 the median scores for most of
the domains were mostly improved or sustained from Cycle 1. At Visit 2 in
the TIS/TIP arm, the median scores were improved from Cycle 1 for the
domains of medication inconvenience (10 units improvement), long-term
treatment (8.3 units improvement) and regime constraints (10 units
improvement). The exception was that median scores decreased in Cycle 2 for
the domains of effectiveness and general. In the COLI/TIP arm, the median
scores were improved from Cycle 1 for the domains of medication
inconvenience (20 units improvement), long-term treatment (12.5 units
improvement) and regime constraints (10 units improvement). In the TIP/TIP
arm, the median scores for most of the domains were high and comparable
between the treatment cycles. Improvements were observed in Cycle 2 for the
domains of medication inconvenience (5 units improvement), regime
constraints (2.5 unit improvement), effectiveness (16.7 units improvement)
and general (8.3 units improvement) (<xref ref-type="table" rid="table4-1753465817710596">Table 4</xref>). Using a separate patient
preference questionnaire, the majority of the patients showed either
&#x02018;strong&#x02019; or &#x02018;somewhat&#x02019; preference to use TIP in the TIS/TIP (9 of 12
patients, 75.0%) and COLI/TIP (18 of 23 patients, 78.3%) arms. &#x02018;Strong&#x02019; or
&#x02018;somewhat&#x02019; preference for TIS and COLI in the TIS/TIP and COLI/TIP arms were
16.7% (2 of 12 patients) and 8.7% (2 of 23 patients), respectively (<xref ref-type="table" rid="table5-1753465817710596">Table 5</xref>).</p><table-wrap id="table5-1753465817710596" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Adverse events, reported by at least two patients, regardless of
study drug relationship, by preferred term and cycle.</p></caption><alternatives><graphic xlink:href="10.1177_1753465817710596-table5"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">TIS/TIP<break/><italic>N</italic> =
14<hr/></th><th align="left" rowspan="1" colspan="1">COLI/TIP<break/><italic>N</italic> =
28<hr/></th><th align="left" rowspan="1" colspan="1">TIP/TIP<break/><italic>N</italic> =
18<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1"><italic>n</italic> (%)</th><th align="left" rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cycle 1</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Number of patients treated in cycle in the analysis
set</td><td rowspan="1" colspan="1">14 (100.0)</td><td rowspan="1" colspan="1">28 (100.0)</td><td rowspan="1" colspan="1">18 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Patients* with AE(s)</td><td rowspan="1" colspan="1">6 (42.9)</td><td rowspan="1" colspan="1">19 (67.9)</td><td rowspan="1" colspan="1">11 (61.1)</td></tr><tr><td rowspan="1" colspan="1">Infective pulmonary exacerbation of cystic fibrosis</td><td rowspan="1" colspan="1">5 (35.7)</td><td rowspan="1" colspan="1">10 (35.7)</td><td rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td rowspan="1" colspan="1">Cough</td><td rowspan="1" colspan="1">2 (14.3)</td><td rowspan="1" colspan="1">2 (7.1)</td><td rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td rowspan="1" colspan="1">Nasopharyngitis</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (10.7)</td><td rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">1 (7.1)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (16.7)</td></tr><tr><td rowspan="1" colspan="1">Sputum increased</td><td rowspan="1" colspan="1">1 (7.1)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (16.7)</td></tr><tr><td rowspan="1" colspan="1">Hemoptysis</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td rowspan="1" colspan="1">Pyrexia</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td rowspan="1" colspan="1">Cycle 2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Number of patients treated in cycle in the analysis
set</td><td rowspan="1" colspan="1">12 (100.0)</td><td rowspan="1" colspan="1">25 (100.0)</td><td rowspan="1" colspan="1">15 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Patients<xref ref-type="table-fn" rid="table-fn22-1753465817710596">*</xref> with
AE(s)</td><td rowspan="1" colspan="1">8 (66.7)</td><td rowspan="1" colspan="1">12 (48.0)</td><td rowspan="1" colspan="1">10 (66.7)</td></tr><tr><td rowspan="1" colspan="1">Infective pulmonary exacerbation of cystic fibrosis</td><td rowspan="1" colspan="1">3 (25.0)</td><td rowspan="1" colspan="1">7 (28.0)</td><td rowspan="1" colspan="1">1 (6.7)</td></tr><tr><td rowspan="1" colspan="1">Cough</td><td rowspan="1" colspan="1">1 (8.3)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">2 (13.3)</td></tr><tr><td rowspan="1" colspan="1">Hemoptysis</td><td rowspan="1" colspan="1">1 (8.3)</td><td rowspan="1" colspan="1">2 (8.0)</td><td rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (20.0)</td></tr><tr><td rowspan="1" colspan="1">Nasopharyngitis</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">3 (20.0)</td></tr><tr><td rowspan="1" colspan="1">Sputum increased</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">0 (0.0)</td><td rowspan="1" colspan="1">2 (13.3)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn22-1753465817710596"><label>*</label><p>Patients with multiple incidences of the same AE are counted only
once for the preferred term.</p></fn><fn id="table-fn23-1753465817710596"><p>AE, adverse events; CI, confidence interval; COLI, colistimethate
sodium; SD, standard deviation; TIP, tobramycin inhalation
powder; TIS, tobramycin inhalation solution.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="section19-1753465817710596"><title>Safety results</title><p>Treatment-emergent AEs (on and off treatment) were reported by 36 patients in
Cycle 1 [(<italic>n/N</italic>, %); TIS/TIP: 6/14, 42.9%; COLI/TIP: 19/28,
67.9%; TIP/TIP: 11/18, 61.1%] and by 30 patients (57.7%) overall in Cycle 2
(Table 6).</p><p>The mean post-inhalation cough rates were comparable between the cycles for the
COLI/TIP arm (0.56 at Visit 2 and 0.47 at Visit 3 <italic>versus</italic> 0.65
at Visit 4 and 0.51 at Visit 5). However, for the TIP/TIP arm, the
post-inhalation cough rate was reduced over time, with a low cough rate in Cycle
2 than in Cycle 1 (0.40 at Visit 4 and 0.33 at Visit 5 <italic>versus</italic>
0.53 at Visit 2 and 0.56 at Visit 3, respectively).</p><p>Treatment-related AEs were reported in four patients (one each in the TIS/TIP and
COLI/TIP arms and two in the TIP/TIP arm) in Cycle 1; none was considered
severe. In Cycle 2, eight patients (15.4%) reported AEs that were suspected to
be treatment related; three were severe (each with decreased FEV<sub>1</sub> and
an upper respiratory tract infection, abnormal acoustic stimulation tests and
tinnitus, and cough). Overall, four patients discontinued the study treatment
due to SAEs; however, none of these events were suspected to be treatment
related.</p><p>The frequency of airway reactivity (i.e. decrease of &#x02a7e;20% in post-dose
FEV<sub>1</sub>% predicted compared with the pre-dose value) from pre-dose
to 15&#x02013;45 min post-dose was low: one patient each at Visits 2 and 3 in the
COLI/TIP arm and one patient at Visit 4 in the TIP/TIP arm.</p></sec></sec><sec sec-type="discussion" id="section20-1753465817710596"><title>Discussion</title><p>Despite recent advances in therapy and improvements in median survival age, the
treatment burden of CF patients has increased, which is primarily associated with
the number of nebulized medications.<sup><xref rid="bibr17-1753465817710596" ref-type="bibr">17</xref></sup><sup><xref rid="bibr18-1753465817710596" ref-type="bibr"/>&#x02013;</sup><sup><xref rid="bibr19-1753465817710596" ref-type="bibr">19</xref></sup> The complexity of nebulized therapy leads to reduced adherence.<sup><xref rid="bibr20-1753465817710596" ref-type="bibr">20</xref></sup>,<sup><xref rid="bibr21-1753465817710596" ref-type="bibr">21</xref></sup> Moreover, lack of adherence with therapy has been considered an important
cause for the increased hospitalization and pulmonary exacerbations in CF patients.<sup><xref rid="bibr17-1753465817710596" ref-type="bibr">17</xref></sup>,<sup><xref rid="bibr22-1753465817710596" ref-type="bibr">22</xref></sup> The ease of use of inhalers is an important factor in encouraging patient
adherence with therapy, minimizing the handling errors and improving satisfaction.<sup><xref rid="bibr17-1753465817710596" ref-type="bibr">17</xref></sup>,<sup><xref rid="bibr23-1753465817710596" ref-type="bibr">23</xref></sup> The present study showed that patients took significantly lower cumulative
time to administer TIP than COLI or TIS. This resulted in approximately 13&#x02013;33 min of
time saving per administration with the T-326 inhaler used for TIP compared with
nebulizers used for TIS and COLI. Ease of T-326 inhaler use for administration of
TIP and reduction in administration time have been associated with improved
adherence and clinical outcomes.<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup> In general, treatment satisfaction, as assessed by TSQM and ACCEPT&#x000ae;
questionnaires showed better results for TIP, with higher scores for &#x02018;convenience&#x02019;
and greater acceptance for TIP, although there were decreases in scores reported in
Cycle 2 compared with Cycle 1 in some of the domains for both the TSQM and ACCEPT&#x000ae;
questionnaires. These patient-reported outcome measures were supported by the
shorter cumulative administration time for TIP and a comparable efficacy profile as
reported in other studies.<sup><xref rid="bibr11-1753465817710596" ref-type="bibr">11</xref></sup> Furthermore, when assessing the patient&#x02019;s preference of inhaled therapy, the
majority of patients showed either &#x02018;strong&#x02019; or &#x02018;somewhat&#x02019; treatment preference for
TIP in the TIS/TIP and COLI/TIP arms over the nebulizers, which emphasizes the ease
of use of TIP over other nebulized drugs.</p><p>Several published studies have described frequent contamination of home nebulizers
with microorganisms and reported that <italic>Pa</italic> constitutes the major contaminant.<sup><xref rid="bibr2-1753465817710596" ref-type="bibr">2</xref></sup>,<sup><xref rid="bibr8-1753465817710596" ref-type="bibr">8</xref></sup> In the present study, the majority of pathogens were isolated from the
nebulizer used to administer COLI in Cycle 1. The microbial contamination assessment
suggested that the T-326 inhaler used for TIP was much less frequently contaminated,
thus potentially reducing the sources of infection in CF patients compared with the
nebulizers used for TIS or COLI. These results advocate the use of T-326 inhaler
over nebulizers.</p><p>Consistent with previous studies,<sup><xref rid="bibr11-1753465817710596" ref-type="bibr">11</xref></sup>,<sup><xref rid="bibr12-1753465817710596" ref-type="bibr">12</xref></sup> sputum <italic>Pa</italic> densities decreased in all the treatment arms.
Although the mean FEV<sub>1</sub>% predicted at the end of the on-treatment period
in Cycle 1 showed a decrease in the TIP arm, and increases in the COLI and TIS arms,
the mean FEV<sub>1</sub>% predicted by the end of the on-treatment period in Cycle 2
remained stable across the three arms. Overall, TIP showed comparable efficacy with
TIS and COLI, which is in accordance with previous publications.<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup>,<sup><xref rid="bibr17-1753465817710596" ref-type="bibr">17</xref></sup>,<sup><xref rid="bibr24-1753465817710596" ref-type="bibr">24</xref></sup>,<sup><xref rid="bibr25-1753465817710596" ref-type="bibr">25</xref></sup></p><p>In addition, this study demonstrated that AEs were comparable in all three treatment
arms and no unexpected safety events were reported. Although cough is a common AE
with inhaled therapies,<sup><xref rid="bibr25-1753465817710596" ref-type="bibr">25</xref></sup>,<sup><xref rid="bibr26-1753465817710596" ref-type="bibr">26</xref></sup> a clear trend was observed in the decreased frequency of post-inhalation
cough over time from Cycle 1 to Cycle 2 in the TIP/TIP arm. Moreover, most cough
events were of mild or moderate intensity in all the arms. Overall, TIP was well
tolerated and the safety findings observed for TIP in this study were generally
consistent with its established safety profile.<sup><xref rid="bibr6-1753465817710596" ref-type="bibr">6</xref></sup>,<sup><xref rid="bibr12-1753465817710596" ref-type="bibr">12</xref></sup>,<sup><xref rid="bibr26-1753465817710596" ref-type="bibr">26</xref></sup></p><p>These results provide clinicians with further guidance on the relative differences
between the speed and ease of use of inhalers and nebulizers as well as evidence on
the prevalence of microbial contamination of the inhalation devices in the
real-world setting. However, this was an open-label, non-randomized study, which
carries the risk of reporting bias, particularly for the patient-reported outcomes.
In addition, data on the nebulizer type were not collected, and therefore, results
are applicable to nebulizers in general but not necessarily to any specific
nebulizer.</p></sec><sec sec-type="conclusions" id="section21-1753465817710596"><title>Conclusions</title><p>In summary, the T-326 inhaler used to deliver TIP showed significantly shorter
administration and cleaning times compared with nebulizers used for COLI and TIS,
suggesting that TIP is easy to use in CF patients treated for pulmonary
<italic>Pa</italic> infection. Ease of use was also supported by the outcomes of
the TSQM and ACCEPT&#x000ae; questionnaires. Furthermore, the T-326 inhaler was much less
frequently contaminated than the nebulizers, thus potentially reducing the sources
of pathogenic bacteria in CF patients. In addition, this study provides further
evidence on the efficacy of TIP as shown by the sustained suppression of
<italic>Pa</italic> and stability in FEV<sub>1</sub>% predicted.</p></sec></body><back><ack><p>The authors acknowledge Anupama Tamta (Novartis Healthcare Pvt. Ltd., Hyderabad,
India) for providing medical writing assistance for this manuscript. This research
was registered at ClinicalTrials.gov [ClinicalTrials.gov identifier:
NCT01844778].</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> JG received honorarium for participation in a Novartis-sponsored advisory board
and received educational grants to attend conferences from Novartis. CS received
financial support from Novartis for an investigator-initiated trial. US, EFN,
and MT have nothing to disclose. WC, PM, LD, and KH are full-time employees of
Novartis Pharmaceuticals Corporation (East Hanover, NJ, USA).</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The study was sponsored by Novartis Pharma AG (Basel, Switzerland).</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1753465817710596"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>BW</given-names></name><name><surname>Pepe</surname><given-names>MS</given-names></name><name><surname>Quan</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Intermittent administration of inhaled
tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled
Tobramycin Study Group</article-title>. <source>N Engl J Med</source>
<year>1999</year>; <volume>340</volume>:
<fpage>23</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">9878641</pub-id></mixed-citation></ref><ref id="bibr2-1753465817710596"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Della Zuana</surname><given-names>A</given-names></name><name><surname>Garcia Dde</surname><given-names>O</given-names></name><name><surname>Juliani</surname><given-names>RC</given-names></name><etal/></person-group>
<article-title>Effect that an educational program for cystic
fibrosis patients and caregivers has on the contamination of home
nebulizers</article-title>. <source>J Bras Pneumol</source>
<year>2014</year>; <volume>40</volume>:
<fpage>119</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">24831395</pub-id></mixed-citation></ref><ref id="bibr3-1753465817710596"><label>3</label><mixed-citation publication-type="book">
<collab>TOBI (tobramycin inhalation solution)</collab>.
<article-title>Prescribing information</article-title>. <publisher-loc>East
Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals
Corp</publisher-name>, <year>2015</year>.</mixed-citation></ref><ref id="bibr4-1753465817710596"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flume</surname><given-names>PA</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>BP</given-names></name><name><surname>Robinson</surname><given-names>KA</given-names></name><etal/></person-group>
<article-title>Cystic fibrosis pulmonary guidelines: chronic
medications for maintenance of lung health</article-title>. <source>Am J
Respir Crit Care Med</source>
<year>2007</year>; <volume>176</volume>:
<fpage>957</fpage>&#x02013;<lpage>969</lpage>.<pub-id pub-id-type="pmid">17761616</pub-id></mixed-citation></ref><ref id="bibr5-1753465817710596"><label>5</label><mixed-citation publication-type="book">
<collab>Promixin&#x000ae;</collab>. <article-title>Summary of product
characteristics</article-title>. <publisher-loc>Profile Pharma
Limited</publisher-loc>: <publisher-name>Chichester</publisher-name>
(WestSussex), <year>2015</year>.</mixed-citation></ref><ref id="bibr6-1753465817710596"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Flume</surname><given-names>PA</given-names></name><name><surname>Kappler</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Safety, efficacy and convenience of tobramycin
inhalation powder in cystic fibrosis patients: the EAGER
trial</article-title>. <source>J Cyst Fibros</source>
<year>2011</year>; <volume>10</volume>:
<fpage>54</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21075062</pub-id></mixed-citation></ref><ref id="bibr7-1753465817710596"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Briesacher</surname><given-names>BA</given-names></name><name><surname>Quittner</surname><given-names>AL</given-names></name><name><surname>Saiman</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Adherence with tobramycin inhaled solution and
health care utilization</article-title>. <source>BMC Pulm Med</source>
<year>2011</year>; <volume>11</volume>: <fpage>5</fpage>.<pub-id pub-id-type="pmid">21251275</pub-id></mixed-citation></ref><ref id="bibr8-1753465817710596"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blau</surname><given-names>H</given-names></name><name><surname>Mussaffi</surname><given-names>H</given-names></name><name><surname>Mei Zahav</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Microbial contamination of nebulizers in the
home treatment of cystic fibrosis</article-title>. <source>Child Care Health
Dev</source>
<year>2007</year>; <volume>33</volume>:
<fpage>491</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">17584406</pub-id></mixed-citation></ref><ref id="bibr9-1753465817710596"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lester</surname><given-names>MK</given-names></name><name><surname>Flume</surname><given-names>PA</given-names></name><name><surname>Gray</surname><given-names>SL</given-names></name><etal/></person-group>
<article-title>Nebulizer use and maintenance by cystic fibrosis
patients: a survey study</article-title>. <source>Respir Care</source>
<year>2004</year>; <volume>49</volume>:
<fpage>1504</fpage>&#x02013;<lpage>1508</lpage>.<pub-id pub-id-type="pmid">15571641</pub-id></mixed-citation></ref><ref id="bibr10-1753465817710596"><label>10</label><mixed-citation publication-type="book">
<collab>TOBI Podhaler (tobramycin inhalation powder)</collab>.
<article-title>Prescribing information</article-title>. <publisher-loc>East
Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals
Corp</publisher-name>, <year>2015</year>.</mixed-citation></ref><ref id="bibr11-1753465817710596"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galeva</surname><given-names>I</given-names></name><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Tobramycin inhalation powder manufactured by
improved process in cystic fibrosis: the randomized EDIT
trial</article-title>. <source>Curr Med Res Opin</source>
<year>2013</year>; <volume>29</volume>:
<fpage>947</fpage>&#x02013;<lpage>956</lpage>.<pub-id pub-id-type="pmid">23672633</pub-id></mixed-citation></ref><ref id="bibr12-1753465817710596"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Geller</surname><given-names>DE</given-names></name><name><surname>Minic</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Tobramycin inhalation powder for P. aeruginosa
infection in cystic fibrosis: the EVOLVE trial</article-title>.
<source>Pediatr Pulmonol</source>
<year>2011</year>; <volume>46</volume>:
<fpage>230</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">20963831</pub-id></mixed-citation></ref><ref id="bibr13-1753465817710596"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>J</given-names></name><name><surname>Vaughan</surname><given-names>S</given-names></name><name><surname>Parkins</surname><given-names>MD.</given-names></name></person-group>
<article-title>Tobramycin Inhalation Powder (TIP): an efficient treatment
strategy for the management of chronic pseudomonas aeruginosa infection in
cystic fibrosis</article-title>. <source>Clin Med Insights Circ Respir Pulm
Med</source>
<year>2013</year>; <volume>7</volume>:
<fpage>61</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">24324354</pub-id></mixed-citation></ref><ref id="bibr14-1753465817710596"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Burke</surname><given-names>LB</given-names></name><name><surname>Powers</surname><given-names>JH</given-names></name><etal/></person-group>
<article-title>Patient-reported outcomes to support medical
product labeling claims: FDA perspective</article-title>. <source>Value
Health</source>
<year>2007</year>; <volume>10</volume>(<issue>Suppl 2</issue>):
<fpage>S125</fpage>&#x02013;<lpage>S137</lpage>.<pub-id pub-id-type="pmid">17995471</pub-id></mixed-citation></ref><ref id="bibr15-1753465817710596"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>MJ</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Hass</surname><given-names>SL</given-names></name><etal/></person-group>
<article-title>Validation of a general measure of treatment
satisfaction, the Treatment Satisfaction Questionnaire for Medication
(TSQM), using a national panel study of chronic disease</article-title>.
<source>Health Qual Life Outcomes</source>
<year>2004</year>; <volume>2</volume>: <fpage>12</fpage>.<pub-id pub-id-type="pmid">14987333</pub-id></mixed-citation></ref><ref id="bibr16-1753465817710596"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Regnault</surname><given-names>A</given-names></name><name><surname>Balp</surname><given-names>MM</given-names></name><name><surname>Kulich</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Validation of the treatment satisfaction
questionnaire for medication in patients with cystic
fibrosis</article-title>. <source>J Cyst Fibros</source>
<year>2012</year>; <volume>11</volume>:
<fpage>494</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">22583743</pub-id></mixed-citation></ref><ref id="bibr17-1753465817710596"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harrison</surname><given-names>MJ</given-names></name><name><surname>McCarthy</surname><given-names>M</given-names></name><name><surname>Fleming</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Inhaled versus nebulised tobramycin: a
real-world comparison in adult cystic fibrosis (CF)</article-title>.
<source>J Cyst Fibros</source>
<year>2014</year>; <volume>13</volume>:
<fpage>692</fpage>&#x02013;<lpage>698</lpage>.<pub-id pub-id-type="pmid">24815094</pub-id></mixed-citation></ref><ref id="bibr18-1753465817710596"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>GS</given-names></name><name><surname>Sellers</surname><given-names>DE</given-names></name><name><surname>Robinson</surname><given-names>WM.</given-names></name></person-group>
<article-title>High treatment burden in adults with cystic fibrosis: challenges
to disease self-management</article-title>. <source>J Cyst Fibros</source>
<year>2009</year>; <volume>8</volume>:
<fpage>91</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">18952504</pub-id></mixed-citation></ref><ref id="bibr19-1753465817710596"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geller</surname><given-names>DE</given-names></name><name><surname>Weers</surname><given-names>J</given-names></name><name><surname>Heuerding</surname><given-names>S.</given-names></name></person-group>
<article-title>Development of an inhaled dry-powder formulation of tobramycin
using PulmoSphere technology</article-title>. <source>J Aerosol Med Pulm
Drug Deliv</source>
<year>2011</year>; <volume>24</volume>:
<fpage>175</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">21395432</pub-id></mixed-citation></ref><ref id="bibr20-1753465817710596"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agent</surname><given-names>P</given-names></name><name><surname>Parrott</surname><given-names>H.</given-names></name></person-group>
<article-title>Inhaled therapy in cystic fibrosis: agents, devices and
regimens</article-title>. <source>Breathe (Sheff)</source>
<year>2015</year>; <volume>11</volume>:
<fpage>110</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="pmid">26306111</pub-id></mixed-citation></ref><ref id="bibr21-1753465817710596"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Latchford</surname><given-names>G</given-names></name><name><surname>Duff</surname><given-names>A</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Adherence to nebulised antibiotics in cystic
fibrosis</article-title>. <source>Patient Educ Couns</source>
<year>2009</year>; <volume>75</volume>:
<fpage>141</fpage>&#x02013;<lpage>144</lpage>.<pub-id pub-id-type="pmid">18952395</pub-id></mixed-citation></ref><ref id="bibr22-1753465817710596"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>GS</given-names></name><name><surname>Heller</surname><given-names>KS</given-names></name><name><surname>Demars</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Motivating adherence among adolescents with
cystic fibrosis: youth and parent perspectives</article-title>.
<source>Pediatr Pulmonol</source>
<year>2015</year>; <volume>50</volume>:
<fpage>127</fpage>&#x02013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">24616259</pub-id></mixed-citation></ref><ref id="bibr23-1753465817710596"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Von Schantz</surname><given-names>S</given-names></name><name><surname>Katajavuori</surname><given-names>N</given-names></name><name><surname>Antikainen</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Evaluation of dry powder inhalers with a focus
on ease of use and user preference in inhaler-naive
individuals</article-title>. <source>Int J Pharm</source>
<year>2016</year>; <volume>509</volume>:
<fpage>50</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">27208655</pub-id></mixed-citation></ref><ref id="bibr24-1753465817710596"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Flume</surname><given-names>PA</given-names></name><name><surname>Galeva</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>One-year safety and efficacy of tobramycin
powder for inhalation in patients with cystic fibrosis</article-title>.
<source>Pediatr Pulmonol</source>
<year>2016</year>; <volume>51</volume>:
<fpage>372</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">26709158</pub-id></mixed-citation></ref><ref id="bibr25-1753465817710596"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schuster</surname><given-names>A</given-names></name><name><surname>Haliburn</surname><given-names>C</given-names></name><name><surname>Doring</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Safety, efficacy and convenience of
colistimethate sodium dry powder for inhalation (Colobreathe DPI) in
patients with cystic fibrosis: a randomised study</article-title>.
<source>Thorax</source>. <year>2013</year>; <volume>68</volume>:
<fpage>344</fpage>&#x02013;<lpage>350</lpage>.<pub-id pub-id-type="pmid">23135343</pub-id></mixed-citation></ref><ref id="bibr26-1753465817710596"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geller</surname><given-names>DE</given-names></name><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Novel tobramycin inhalation powder in cystic
fibrosis subjects: pharmacokinetics and safety</article-title>.
<source>Pediatr Pulmonol</source>
<year>2007</year>; <volume>42</volume>:
<fpage>307</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">17352404</pub-id></mixed-citation></ref><ref id="bibr27-1753465817710596"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Stanojevic</surname><given-names>S</given-names></name><name><surname>Cole</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Multi-ethnic reference values for spirometry for
the 3&#x02013;95-yr age range: the global lung function 2012
equations</article-title>. <source>Eur Respir J</source>
<year>2012</year>; <volume>40</volume>:
<fpage>1324</fpage>&#x02013;<lpage>1343</lpage>.<pub-id pub-id-type="pmid">22743675</pub-id></mixed-citation></ref></ref-list></back></article>